Inspired by Children

Similar documents
The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

Antimicrobial Resistance Update for Community Health Services

Impact of NHS England Quality Indicators on Antimicrobial Resistance. Professor Alan Johnson National Infection Service Public Health England

Advances in Antimicrobial Stewardship (AMS) at University Hospital Southampton

Surveillance of AMR in PHE: a multidisciplinary,

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Antibiotic Review Kit - Hospital

FIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance

What s happening across the UK with antimicrobial prescribing quality indicators?

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland

Models for stewardship in Hospital - UK Models Philip Howard Consultant Antimicrobial Pharmacist

Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018

Role of the general physician in the management of sepsis and antibiotic stewardship

Antimicrobial Cycling. Donald E Low University of Toronto

EARS Net Report, Quarter

Promoting Appropriate Antimicrobial Prescribing in Secondary Care

Part 2c and 2d CQUIN 2018/19 webinar, 22 February 2018 Answers to questions asked

Prescribing Quality Scheme 2017/18

Acute Pyelonephritis POAC Guideline

9.4 Antimicrobial Resistance

Multi-drug resistant microorganisms

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

9.5 Antimicrobial Resistance

Report on Antimicrobial Use and Resistance in Humans in 2012

Antimicrobial Stewardship in Scotland

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

Introduction to antimicrobial resistance

Quality indicators and outcomes in the devolved nations Scotland

How is Ireland performing on antibiotic prescribing?

Antimicrobial resistance and the need for stewardship. Dr Nick Brown RCP Acute Medicine conference, 16 April 2018

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Nosocomial Infections: What Are the Unmet Needs

WHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible

Antibiotic courses and antibiotic conservation, getting the balance right

Vaccine Evaluation Center, BC Children s Hospital Research Institute, 950 West 28 th Ave,

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

ANTIMICROBIAL STEWARDSHIP START SMART THEN FOCUS Guidance for Antimicrobial Stewardship for SHSCT

Stratégie et action européennes

Antimicrobial Stewardship:

The threat of multidrug-resistant microorganisms and how to deal with it in Europe

Antimicrobial Resistance Strains

Summary of the latest data on antibiotic resistance in the European Union

2015 Antimicrobial Susceptibility Report

Fighting MDR Pathogens in the ICU

The trinity of infection management: United Kingdom coalition statement

ESCMID Online Lecture Library. by author

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

GENERAL NOTES: 2016 site of infection type of organism location of the patient

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening

Epidemiology and Economics of Antibiotic Resistance

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

Prevention & Management of Infection post Trans Rectal Ultrasound (TRUS) biopsy

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Carbapenemase-Producing Enterobacteriaceae (CPE)

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital

MRSA in the United Kingdom status quo and future developments

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

Infection Control of Emerging Diseases

The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24

North West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families

Implementing the UK Five Year Antimicrobial Resistance Strategy

Please distribute a copy of this information to each provider in your organization.

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Summary of the latest data on antibiotic consumption in the European Union

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Resistant Gram-negative Bacteria

Antimicrobial resistance (EARS-Net)

CQUIN 2016/17. Anti-Microbial Resistance (AMR) Frequently Asked Questions

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Fluid Therapy and Heat Injuries in Multi Purpose Canines (MPC) PFN: SOMVML0R. Terminal Learning Objective. References. Hours: Instructor:

Antimicrobial Resistance and Dentistry. LDC Officials Day 4 December 2015 Susie Sanderson

What bugs are keeping YOU up at night?

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

A snapshot of polymyxin use around the world South America

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Witchcraft for Gram negatives

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

International Food Safety Authorities Network (INFOSAN) Antimicrobial Resistance from Food Animals

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

CONTAGIOUS COMMENTS Department of Epidemiology

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

Scottish Medicines Consortium

Workplan on Antibiotic Usage Management

Antibiotic stewardship in long term care

Understanding the Hospital Antibiogram

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria

Antimicrobial Stewardship. Where are we now and where do we need to go?

Infection Prevention and Control Policy

Transcription:

Complexities in the early recognition and treatment of meningitis and septicaemia: The unstoppable force of sepsis hitting the immovable object of antibiotic resistance? Inspired by Children

Decreasing admissions for meningitis and septicaemia. Lancet Infect Dis. 2014;14:397-405

Increasing hospital admissions for children. Arch Dis Child. 2013;98:328-34

Very low rates of culture-confirmed invasive bacterial infections. Arch Dis Child. 2014;99:526-31 5 Hospitals in SW London, over 3 years 46,039 admissions Blood/CSF cultures obtained during 45% of admissions 2.4% (504) clinically significant 1.1% of hospital admissions Incidence of community-acquired invasive bacterial infection only 6.4/100 000

Finding a needle in a haystack?

Feverish illness in children Assessment and initial management in children younger than 5 years NICE clinical guideline 160

Colour Activity Respiratory Circulation and Hydration Other LOW RISK INTERMEDIATE RISK HIGH RISK Normal colour of skin lips or tongue Responds normally to social cues Content / smiles Stays awake or awakens quickly Strong normal cry / not crying AND NONE OF THE AMBER OR RED SYMPTOMS OR SIGNS Pallor reported by parent / carer Not responding normally to social cues Wakes only with prolonged stimulation Decreased activity No smile Nasal flaring age <12 months Tachypnoea: RR >50bpm age 6-12 months RR >40bpm age >12 months Oxygen saturation < 95% in air Crackles in the chest Dry mucous membrane Poor feeding in infants * Capillary refill time >=3 seconds Reduced urine output Tachycardia: > 160 beats/minute, age < 1 year > 150 beats/minute, age 1-2 years > 140 beats/minute, age 2-5years Swelling of a limb or joint Non weight bearing limb/ not using an extremity Rigors Fever for >= 5 days Age 3-6months Temp >=39 o C Pale / mottled / ashen / blue No response to social overtures Ill appearing to a healthcare professional Unable to rouse or if roused does not stay awake Weak / high pitched /continuous cry Grunting Tachypnoea RR > 60bpm Moderate to severe chest indrawing Give immediate parenteral antibiotics to children if they are: Normal Skin and Eyes Reduced Skin turgor - shocked Moist mucus membrane - unrousable - showing signs of meningococcal disease. Non blanching rash Bulging fontanelle Neck stiffness Focal neurological signs Focal seizures Age 0-3months Temp >=38 o C

Colour Activity Respiratory Circulation and Hydration LOW RISK INTERMEDIATE RISK HIGH RISK Normal colour of skin lips or tongue Responds normally to social cues Content / smiles Stays awake or awakens quickly Strong normal cry / not crying Normal Skin and Eyes Moist mucus membrane Pallor reported by parent / carer Not responding normally to social cues Wakes only with prolonged stimulation Decreased activity No smile For children aged under 5 years who have suspected sepsis and 1 or more high risk criteria: Nasal flaring age <12 months Crackles in the chest Dry mucous membrane Poor feeding in infants * Capillary refill time >=3 seconds Reduced urine output - give a broad-spectrum antimicrobial at the maximum recommended dose within 1 hour Pale / mottled / ashen / blue No response to social overtures Ill appearing to a healthcare professional Unable to rouse or if roused does not stay awake Weak / high pitched /continuous cry Grunting Apnoea Tachypnoea: RR >50bpm age 6-12 months RR >40bpm age >12 months Oxygen saturation < 90% in air Reduced Skin turgor Tachycardia: > 160 beats/minute, age < 1 year > 150 beats/minute, age 1-2 years > 140 beats/minute, age 2-5years < 60 beats/minute, any age Other AND NONE OF THE AMBER OR RED SYMPTOMS OR SIGNS Swelling of a limb or joint Non weight bearing limb/ not using an extremity Rigors Non blanching rash Bulging fontanelle Neck stiffness Focal neurological signs Focal seizures Fever for >= 5 days Age 3-6months Temp >=39 o C Age 0-3months Temp >=38 o C Any age Temp <36 o C

Deriving temperature and age appropriate heart rate centiles for children with acute infections Arch Dis Child. 2009;94:361-5 1589 children with self limiting infections Heart rate increased by 10 bpm with each 1 degrees C increment in temperature

Pulse in children with meningococcal septicaemia Arch Dis Child. 2011; 96: 368 373.

NICE Sepsis guideline in use. Arch Dis Child. 2018. pii: archdischild-2018-314865 Paediatric Emergency Dept; Feb - May 2017. 4322 children attended 216 (5%) had one or more high-risk criterion. 159 children (73%) tachycardia. Senior decision-making doctor gave 17 (7.8%) intravenous antibiotics 1 child had bacteraemia

Every action has an equal and opposite reaction

Antibiotics Natural selection

Antibiotics Natural selection

Natural selection

year-on-year, from 9.6% in 2012 to 11.6% in 2015, showed only a marginal increase to 11.8% in 2016, while resistance to co-amoxiclav, which had increased from 37.3% in 2012 to 42.3% in 2015 decreased to 40.8% in 2016 (Figure 2.1). Carbapenem resistance fluctuated from year-to-year within the range 0.07-0.14%, with between 15 to 32 isolates reported from blood in an individual year, with no consistent time trend. % Non-susceptible 60 50 40 30 45,000 40,000 35,000 30,000 25,000 English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2017 20,000 20 15,000 10 10,000 5,000 0 0 resistance to ciprofloxacin, 2012 third-generation 2013 2014 cephalosporins, 2015 gentamicin 2016 and carbapenems fluctuating within the ranges 10.0-11.5%, 11.1-12.3%, 7.1-8.9% and 0.8- Year 1.5%, respectively. Co-amoxiclav Resistance to piperacillin/tazobactam, Ciprofloxacin which had increased year-onyear from 3rd-generation 13.3% in 2012 cephalosporins to 18.6% 2015, showed Piperacillin/tazobactam a slight reduction to 17.8% in 2016. Similarly, Gentamicin resistance to co-amoxiclav, which had Carbapenems increased year-on-year from 19.7% to 28.4% between 2012 to 2015, decreased slightly to 27.5% in 2016 (Figure 2.3). Figure 2.1 Number of bloodstream isolates of E. coli reported to the mandatory The surveillance proportions scheme of bloodstream and the isolates proportions of K. pneumoniae non-susceptible resistant to indicated combinations antibiotics of antibiotic classes also remained stable between 2012 and 2016, albeit with some yearto-year The proportions variation. Multi-resistance of bloodstream varied isolates in the of E. range coli showing of 3-8%, with multi-resistance the highest also proportions remained stable seen for between combinations 2012 and of third-generation 2016 and varied cephalosporins, the range of aminoglycosides 3-5%; the highest and proportions piperacillin/tazobactam were seen for and combinations the lowest of for third-generation cephalosporins, quinolones quinolones and piperacillin/tazobactam (Figure 2.4). and aminoglycosides and the lowest for third-generation cephalosporins, aminoglycosides and piperacillin/tazobactam (Figure 2.2). 50 7000 Although the proportions of E. coli blood culture isolates with resistance to either 6000 individual 40 or combinations of key antibiotics remained fairly stable between 5000 2012 and 2016, 30the incidence of E. coli bacteraemia increased year-on-year, from 32,405 4000 cases in 2012 20 to 40,272 cases in 2016, an overall increase over the five-year period 3000 of 24.3% (Figure 2.1). Thus, the burden of resistance as reflected in the estimated numbers 2000 of 10 antibiotic-resistant bloodstream infections (derived using the numbers of infections 1000 and the proportions 0 of resistant isolates each year shown in Figures 2.1 and 2.2) 0 increased 2012 2013 2014 2015 2016 year-on-year. For example, the estimated numbers of ciprofloxacin-resistant infections increased Co-amoxiclav Year from 5,930 in 2012 to 7,490 in 2016, while Ciprofloxacin infections resistant to thirdgeneration cephalosporins increased from 3,500 in 2012 to 4,995 in 2016. The 3rd-generation cephalosporins Piperacillin/tazobactam Gentamicin Carbapenems estimated Counts numbers of K. pneumoniae* of infections (SGSS) due to E. coli with combined resistance to third- *based on voluntary SGSS CDR laboratory reports 14 Figure 2.3 Number of bloodstream isolates of K. pneumoniae reported to SGSS and the proportions non-susceptible to indicated antibiotics % Non-susceptible E. coli in blood K. pneumoniae in blood Although the proportions of blood culture isolates of K. pneumoniae resistant to a number of key antibiotics remained fairly stable between 2012 and 2016, reports of bacteraemia due to K. pneumoniae showed an overall increase between 2012 and 2016 (Figure 2.3), indicating that the burden of resistance to these antibiotics as reflected in No. reports No. reports No. confirmed carbapenemases 3000 2500 2000 1500 1000 500 Carbapenemases from CPE 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Year FRI SME IMP + NDM OXA-48 + VIM KPC + NDM KPC + OXA-48 NDM + OXA-48 KPC + VIM VIM + NDM IMI GES NDM OXA-48 KPC VIM IMP English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2017 Figure 2.10 Carbapenemases produced by CPE referred to the PHE AMRHAI Reference Unit In addition to the big 5 carbapenemase 4% 2% 5% 3% families, other less common carbapenemase types including GES, IMI, SME and FRI were detected and there is evidence that som are circulating in the UK. GP / Community 1. GES (Guiana extended-spectrum (GES) β-lactamases can NHS confer Acute carbapenemase Trust (A & E) or extended-spectrum β-lactamase (ESBL) activity depending NHS on Trust the (In-patient) gene variant. GES carbapenemases have been identified by AMRHAI in NHS P. aeruginosa Trust (Out-patient) (particularly sequence type [ST] 235) and various species of Enterobacteriaceae since 2012. 20 Other Isolates have mostly been sporadic. Exceptions are: (i) a laboratory i the North East that has submitted GES-5 carbapenemase-positive P. aeruginosa ST235 since 2012; and (ii) an outbreak involving GES-5-positive K. oxytoca in a London hospital in 2015. 86% 21 Whilst AMRHAI has been able to identify potential markers for GES carbapenemase production in the antibiograms of P. aeruginosa, phenotypic detection of CPE producing GES is complicated by the diverse range o carbapenem MICs noted in positive isolates received to date, meaning that some Figure 2.13 Location of patient recorded on ERS with confirmed CPE (May GES 2015 carbapenemase-positive May 2017) isolates may be misinterpreted as ESBL producers with reduced susceptibility to the carbapenems contingent upon porin loss. =Antibiotic resistance in Neisseria gonorrhoeae Resistance in N. gonorrhoeae is a major concern globally, as it has emerged for all

What about new antibiotics? Boucher, Clin Inf Dis, 2013

What is AMS? - only prescribe antimicrobials when clinically appropriate - review intravenous antimicrobial prescriptions at 48 72 hours

CQUINs National CQUIN targets for Antimicrobial Prescribing in 2017/18 to 2018/19 CQUIN = Commissioning for Quality and Innovation (CQUIN) payments

CQUINs Commissioning for Quality and Innovation payments The CQUIN scheme is intended to deliver clinical quality improvements and drive transformation change. These will impact on reducing inequalities in access to services, the experiences of using them and the outcomes achieved. NHS England

CQUINs A B I O T A B I O T Worth approx. 120,000/year

Sepsis Antimicrobial Stewardship

Sepsis Give antibiotics quickly Antimicrobial Stewardship Stop antibiotics quickly